Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice [PDF]
Scientific ReportsMedication-related osteonecrosis of the jaw (MRONJ) is a detrimental side effect in patients undergoing treatment with antiresorptive agents. The anti-angiogenic agent, bevacizumab (anti-VEGF antibody (Ab)), has also been reported to be associated with ...
Eun-Bin Bae +11 more
doaj +2 more sources
The efficacy and safety of intraocular anti-VEGF injections versus anti-VEGF combined with steroids or steroid monotherapy for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis of randomized controlled trials [PDF]
Frontiers in MedicineObjectiveThe study performed a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the efficacy and safety of intraocular injections of anti-vascular endothelial growth factor (VEGF) monotherapy versus steroid monotherapy
Han Cai +3 more
doaj +2 more sources
Management of coexisting cataract and diabetic macular edema: a comparative study of dexamethasone implant versus anti-VEGF agents injections. [PDF]
Int J OphthalmolKelkar A +5 more
europepmc +2 more sources
Anti-VEGF drugs: evidence for effectiveness
Community Eye Health Journal, 2014 Anti-vascular endothelial growth factors (anti-VEGF) are targeted biological drugs (e.g. monoclonal antibodies) that prevent the growth of new vessels by inhibiting VEGF.
Jennifer Evans , Gianni Virgili
doaj +2 more sources
Journal of Ophthalmology, 2021 Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti-VEGF) is the first-line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns.
Di Zou, Imran Jawaid, Winfried M. Amoaku
doaj +1 more source
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Computational and Systems Oncology, 2021 Vascular endothelial growth factor (VEGF) is a strong promoter of angiogenesis in tumors, and anti‐VEGF treatment, such as a humanized antibody to VEGF, is clinically used as a monotherapy or in combination with chemotherapy to treat cancer patients ...
Ding Li, Stacey D. Finley
doaj +1 more source
BMJ Open, 2023 Objectives To evaluate the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for myopia choroidal neovascularisation (CNV), and to compare the efficacy of two different anti-VEGF retreatment criteria.Data sources PubMed ...
Chao Zhang +5 more
doaj +1 more source
VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Annals of Medicine, 2022 Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries.
Alessandro Arrigo +2 more
doaj +1 more source
Journal of Ophthalmology, 2021 Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti-vascular endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of macular edema (ME) caused by retinal vein occlusion (RVO). Methods.
Young Hwan Bae +5 more
doaj +1 more source
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]
, 2020 Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery +30 more
core +4 more sources